This state-of-the-art facility provides advanced flow cytometric and morphology services at cellular and subcellular levels of resolution. The services offered by the Flow and Image Cytometry Shared Resources (FICSR) include investigator access to equipment 24/7, education and consultation services, comprehensive sample processing, data acquisition and data analysis services, luminex cytokine, chemokine and growth factor quantification, and core flow cytometry services for investigator and biotech sponsored clinical trials.

Our goal is to establish a fully integrated core facility for proteomics analyses at Roswellpark Cancer Institute. There are a variety of electrophoresis based, HPLC-based and mass spectrometry based capabilities for proteomics applications and these can be variously configured depending on the needs of the particular project.Proteomics Resources interacts with other proteomics facilities that are currently being developed at the University of Buffalo. Together the two resources provide essential support for proteomics projects in Buffalo.These resources also provide training and educational programs to faculty, staff and students of RPCI and SUNY at Buffalo. http://www.roswellpark.org/proteomics

The Gene Targeting and Transgenic Resource (GTTR) enables investigators to modify the murine genome for the systematic dissection of the genetic, molecular, cellular and physiological mechanisms underlying complex biological processes.

Traditionally, this has been done by creation of transgenics through pronuclear microinjection and knocking out or knocking in genes via mouse ES cell technologies.

This is no longer the case given the recent advances of genome-editing tools such as ZFNs, TALENs and most recently CRISPR/Cas, which allow for a targeted approach by injection directly into the embryo.

In general, these methods are proving to be faster and more efficient than traditional means.

In addition, the core also provides investigators with mouse reproductive services such as cryopreservation of valuable mouse strains and IVF (in vitro fertilization) to aid in mouse cohort generation, especially when faced with increasing complex genotype demands.

The Center for Immunotherapy, ISO9001:2008 registered Therapeutic Cell Production Facility (TCPF) at the Roswell Park Cancer Institute was designed to fulfill US FDA cGMP requirements in support of cell therapy clinical trials. Occupying 2574 ft2, the TCPF multiuse cleanroom suite is made up of three ISO 7 production rooms and one ISO 7 flex production room. Additionally, an onsite QC laboratory can perform requisite testing for cell therapy investigational products. Suite and production room entry is controlled via an electronic card access security system, with centralized monitoring of air and equipment. The anterooms and production rooms house refrigerators and low-temperature freezers with appropriate data logging capabilities and are connected to a central monitoring system. Dedicated TCPF personnel are responsible for maintaining the cleanroom and equipment as required by the FDA. The TCPF is fully equipped to provide broad and comprehensive cell processing capabilities. The TCPF has expertise to assist with a variety of cell manufacturing needs.

The Gene Targeting and Transgenic Facility at Roswell Park provides investigators in the Western New York area with genetically modified animals for their research through gene targeting and transgenic methodologies.

The Biomolecular Shared Resource provides a suite of services that enable our staff to address a variety of molecularly based research projects. There are three Facilities within the Resource: DNA Sequencing, Proteomics/Mass Spectrometry and Nuclear Magnetic Resonance Spectroscopy (NMR). Our services include Sanger DNA sequencing and fluorescence based DNA fragment analysis; mass spectrometry based proteomics and metabolomics, and NMR spectroscopy. We assist staff in understanding the applications and limitations of various techniques to their research programs through consultation and discussion and development of pilot feasibility studies, as necessary.